Pilot of a Trial Enrollment Diversity Dashboard

NCT06795139 | Active Not Recruiting

• 2 other identifiers: 24-544K08CA273043-01
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.

Conditions

Leukemia; Acute Leukemia

Keywords

Leukemia; Acute Leukemia; Clinical Trial Diversity

Outcome Measures

Primary Outcomes (1)

• TEDD Utilization Rate

  Utilization will be measured as the proportion of quarters where a participant accessed the dashboard divided by the total number of study quarters. Based on 12 participants over 4 three-month quarters, there are a total of 48 person-quarters available for analysis.

  12 months

Study Arms (1)

TEDD Intervention

EXPERIMENTAL

12 medical professional participants will complete the following: * Baseline survey. * Usage and access of the TEDD intervention over a 12-month period. * Follow up surveys at the end of each quarter.

Behavioral: Trial Enrollment Diversity Dashboard Behavioral

Interventions

Trial Enrollment Diversity Dashboard Behavioral BEHAVIORAL

A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.

TEDD Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Physician, nurse practitioner, or physician assistant
• ≥10% clinical effort (or one ½ day of clinic per week for those working \<1 FTE)
• Treats adult patients with leukemia or related diseases at the study sites
• Ability to understand and willingness to provide informed consent
• Age 18 or older
• Age ≥18 years old
• Diagnosis of leukemia, lymphoma, myeloma, or related diseases
• Seen by a physician for this diagnosis at one of the study sites

You may not qualify if:

• Listed member of the research team
• Participants without the diagnoses of interest listed above, participants not seen at the study sites.

Sponsors & Collaborators

• Dana-Farber Cancer Institute: lead
• National Cancer Institute (NCI): collaborator
• American Society of Clinical Oncology: collaborator

Study Sites (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

MeSH Terms

Conditions

Leukemia

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Andrew Hantel, MD

  Dana-Farber Cancer Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: January 22, 2025
• First Posted: January 27, 2025
• Study Start: March 1, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): June 30, 2027
• Last Updated: August 28, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: Data can be shared no earlier than 1 year following the date of publication
• Access Criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Locations

US (1)